Design Therapeutics, Inc. (DSGN): Price and Financial Metrics


Design Therapeutics, Inc. (DSGN): $8.27

-0.22 (-2.59%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add DSGN to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

DSGN Stock Price Chart Interactive Chart >

Price chart for DSGN

DSGN Price/Volume Stats

Current price $8.27 52-week high $26.30
Prev. close $8.49 52-week low $6.94
Day low $8.25 Volume 274,753
Day high $8.63 Avg. volume 438,611
50-day MA $10.56 Dividend yield N/A
200-day MA $15.05 Market Cap 462.38M

Design Therapeutics, Inc. (DSGN) Company Bio


Design Therapeutics, Inc. develops therapies for the treatment of degenerative disorders caused by nucleotide repeat expansions. The company engages in the development of a program for the treatment of Friedreich's ataxia and degenerative diseases such as Fragile X syndrome and myotonic dystrophy. The company was incorporated in 2017 and is based in Carlsbad, California.


DSGN Latest News Stream


Event/Time News Detail
Loading, please wait...

DSGN Latest Social Stream


Loading social stream, please wait...

View Full DSGN Social Stream

Latest DSGN News From Around the Web

Below are the latest news stories about DESIGN THERAPEUTICS INC that investors may wish to consider to help them evaluate DSGN as an investment opportunity.

Independent Director Rodney Lappe Just Bought 15% More Shares In Design Therapeutics, Inc. (NASDAQ:DSGN)

Investors who take an interest in Design Therapeutics, Inc. ( NASDAQ:DSGN ) should definitely note that the Independent...

Yahoo | December 14, 2022

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

We're starting off the day with a look at the biggest pre-market stock movers that traders will want to watch on Thursday!

William White on InvestorPlace | December 8, 2022

Design Therapeutics Reports Positive Data from Single-Ascending Dose Trial of DT-216 for the Treatment of Friedreich Ataxia and Portfolio Progress

DT-216 was Generally Well-Tolerated and Resulted in a More than Doubling of Frataxin mRNA in Patients with Friedreich Ataxia Second GeneTACTM Development Candidate, DT-168, Selected for the Treatment of Fuchs Endothelial Corneal Dystrophy Administered as an Eye Drop; IND Expected in 2023 Advancing Myotonic Dystrophy Type-1 GeneTACTM Lead Molecules; IND Expected in 2024 Conference Call to be Held Today at 4:30pm ET CARLSBAD, Calif., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nas

Yahoo | December 7, 2022

Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

Yahoo | November 28, 2022

Design Therapeutics Highlights Pipeline Progress and Upcoming Milestones and Reports Third Quarter 2022 Financial Results

Initial Data from Single-Ascending Dose Phase 1 Trial of DT-216 for Friedreich Ataxia Expected to be Reported in December 2022 Dosing Initiated in the Multiple-Ascending Dose Phase 1 Trial of DT-216; Trial Completion Anticipated in Mid-2023 Strong Financial Position with $344.2 Million in Cash and Securities to Support Multi-Year Operating Runway and Further Advancement of GeneTAC™ Platform CARLSBAD, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-s

Yahoo | November 3, 2022

Read More 'DSGN' Stories Here

DSGN Price Returns

1-mo -13.40%
3-mo -48.63%
6-mo -57.85%
1-year -27.07%
3-year N/A
5-year N/A
YTD -19.40%
2022 -52.08%
2021 N/A
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7245 seconds.